<DOC>
	<DOCNO>NCT01691326</DOCNO>
	<brief_summary>The aim clinical study demonstrate safety immunogenicity Fluzone vaccine . Objective : - To describe safety 2012-2013 formulation Fluzone vaccine , administer 1- 2-dose schedule , accordance Advisory Committee Immunization Practices ( ACIP ) recommendation , child 6 month &lt; 9 year age . Observational Objectives : - To describe immunogenicity 2012-2013 formulation Fluzone vaccine , administer 1- 2-dose schedule accordance ACIP recommendation , child 6 month &lt; 9 year age . - To submit remain available sera subject Center Biologics Evaluation Research ( CBER ) analysis World Health Organization ( WHO ) , Centers Disease Control Prevention ( CDC ) , Food Drug Administration ( FDA ) support selection recommendation strain subsequent year ' influenza vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine ( 2012-2013 Formulation )</brief_title>
	<detailed_description>All participant receive Fluzone vaccine Visit 1 . For subject receive 2 dos influenza vaccine , per ACIP guidance , second dose Fluzone vaccine administer Visit 2 . Total duration participation study approximately 28 day participant receive 1 dose 56 day receive 2 dos Fluzone vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject 6 month &lt; 9 year age day inclusion Parent/guardian willing able attend schedule visit comply study procedure entire duration study Assent form sign dated subject 7 &lt; 9 year age , informed consent form sign dated parent ( ) another legally acceptable representative For subject 6 month &lt; 24 month age , bear full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg ( 5.5 lb ) . Known systemic hypersensitivity egg , chicken protein , latex , vaccine component , history lifethreatening reaction Fluzone vaccine vaccine contain substance ( complete list vaccine component include Prescribing Information ) History serious adverse reaction influenza vaccine Receipt vaccine within 30 day receive study vaccine , plan receive another vaccine Visit 2 subject receive 1 influenza vaccine Visit 3 subject receive 2 dos influenza vaccine Participation another interventional clinical trial investigate vaccine , drug , medical device , medical procedure 30 day precede first study vaccination course study unless intervention study occur within 30 day prior first study vaccination none plan subject would complete safety surveillance present study Prior vaccination formulation 20122013 influenza vaccine Bleeding disorder receipt anticoagulants 3 week precede inclusion , may contraindication intramuscular ( IM ) vaccination , discretion Investigator Thrombocytopenia , may contraindication IM vaccination , discretion Investigator Any condition opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine Personal history GuillainBarré syndrome Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Personal history clinically significant developmental delay ( discretion Investigator ) , neurologic disorder , seizure disorder Chronic illness , opinion Investigator , stage might interfere trial conduct completion Known seropositivity human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 100.4°F ) . A prospective subject include study condition resolve febrile event subside Receipt immune globulin , blood , bloodderived product past 3 month Identified natural adopt child Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Fluzone® ( Influenza Virus Vaccine ) 2012-2013 Formulation</keyword>
	<keyword>Influenza virus vaccine</keyword>
	<keyword>Trivalent Inactivated Influenza Vaccine</keyword>
</DOC>